clinicaltrials.gov/ct2/show/NCT01831791
Glaxo Kline Smith is launching a clinical trial in a month to begin using Dut as a hairloss treatment. I don’t how we do this, but it would be nice to get some neurosteroid levels in the brain before they begin the trials, that way the men that inevitably get stuck with PFS will be documented, and might help us understand the process better.
Interesting, I thought they had abandoned plans to promote it for hair loss years ago. It doesn’t say much for the impact of PFS research and awareness that they feel they can get away with promoting another 5AR inhibitor for hairloss.
Agreed. This is a sad reflection on the state of the entire industry.
I’d rather trust my health to McDonald’s or Coke or M&M Mars than to Merck – or Glaxo Smith Kline.
Like Dr. Healey said, keep doing studies until you get the results you want.
This arm of the study is in Japan. Surprised it was greenlit by the Japanese MoH. Also note patients are given a cutoff date when they’re allowed to reported an Adverse Event.
Instead to stop the Madness and do a Clinical Trail for PFS Suffer, they try do bring a more potent and dangerous Drug to the World…Fuck this sick World
They discontinued the trials for it in 2002 for the treatment of hair loss for “unknown reasons”. I think they knew the drug was dangerous. I hope this latest study doesnt try and play down the side effects from Dutasteride.
unknown reasons, unknown treatmants, unknown causes what the fuck ıs the secret about thıs shıt pılls? Why stıll are they sellıng?
I think what Glaxo is doing is trying to grab the market from Merck. Since Propecia is now generic, Merck’s profits from the drug are on the wane. But if Galxo can get FDA approval, they can rake in about $200 million annually for–what?–ten years before their patent expires.
Glaxo is also betting that the current PFS studies will put patients off Propecia, so if Glaxo can show that Dutasteride is even, say, 10% more clinically safe than Propecia, they can sell that comparison.
It’s numbers pure and simple.
A sick world we live in, no doubt.
god curse all drug companies. Fuckıng idiots.
Interesting if you look at the parameters of the study - one of the things they list that would preclude men from the study is “A sensitivity to 5AR inhibitors”
That implies they can pre screen for 5ARI sensitive people…do they know something we don’t?
Do you mean where it says “Hypersensitivity to any 5 alpha-reductase (5AR) inhibitor or drugs chemically related to the study treatment” ?
That’s an allergic-immune response. Its a pretty standard exclusion criteria for any medication.
OK. I thought they could somehow predict who would get PFS. I see.
Man - I wish we could get some before and after bloodwork and CSF work for these guys…undoubtedly we are going to have some new PFS guys thanks to this.
ı am almost sure even ıf one day people realıse that pfs ıs real, thıs shıtty drugs still will sell.
GlaxoSmithKline are as bad as merck.
The only difference in morals between a street drug dealer and a pharmaceutical company is that one happens to be legal.
reuters.com/article/2014/04/ … UO20140401
[Size=4]FDA finds contaminated drug ingredients at GSK’s Ireland plant[/size]
(Reuters) - The U.S. Food and Drug Administration found contamination of drug ingredients manufactured at a GlaxoSmithKline Plc plant in Ireland and said the company did not take sufficient action to resolve the problems.
The news comes just days after GSK said it was recalling all supplies of its over-the-counter weight-loss drug in the United States and Puerto Rico, after concerns that bottles had been tampered with.
In a warning letter dated March 18, the FDA said the company did not fully investigate a list of objectional conditions the regulator sent after its inspection of the manufacturing facility at Cork, Ireland in October.
The FDA said its investigator found that a certain drug ingredient, the name of which was not disclosed, was contaminated with material from the facility’s pharmaceutical waste tank. (link.reuters.com/xah28v) (Reporting by Vrinda Manocha in Bangalore; Editing by Maju Samuel)